Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:CLPT NASDAQ:NNOX NASDAQ:NPCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.05+4.1%$1.80$0.76▼$2.73$74.45M1.3185,423 shs67,707 shsCLPTClearPoint Neuro$11.15-5.9%$12.26$6.25▼$19.22$331.67M0.92257,447 shs609,466 shsNNOXNano-X Imaging$4.91-4.7%$5.25$3.75▼$11.00$297.56M1.961.73 million shs2.18 million shsNPCENeuroPace$9.35-2.1%$12.53$5.45▼$18.98$313.23M1.93185,401 shs191,786 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+4.06%-13.50%+17.14%+120.43%+49.64%CLPTClearPoint Neuro-5.91%-5.19%-3.38%-3.21%+48.27%NNOXNano-X Imaging-4.66%-6.12%-2.58%+9.11%-44.71%NPCENeuroPace-2.09%-9.75%-15.54%-10.35%+21.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical2.2013 of 5 stars0.04.00.04.22.71.70.6CLPTClearPoint Neuro1.8298 of 5 stars3.51.00.00.02.40.80.6NNOXNano-X Imaging2.3027 of 5 stars3.52.00.00.03.80.00.6NPCENeuroPace3.5346 of 5 stars3.53.00.00.03.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/ACLPTClearPoint Neuro 3.00Buy$25.00124.22% UpsideNNOXNano-X Imaging 3.25Buy$9.5093.48% UpsideNPCENeuroPace 3.00Buy$17.0081.82% UpsideCurrent Analyst Ratings BreakdownLatest APYX, NPCE, CLPT, and NNOX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025NNOXNano-X ImagingLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/6/2025NNOXNano-X ImagingD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/23/2025NNOXNano-X ImagingD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $10.005/22/2025NNOXNano-X ImagingAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.004/17/2025NNOXNano-X ImagingD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$48.10M1.61N/AN/A$0.38 per share5.39CLPTClearPoint Neuro$31.39M9.94N/AN/A$0.92 per share12.12NNOXNano-X Imaging$11.28M25.15N/AN/A$3.27 per share1.50NPCENeuroPace$79.91M3.84N/AN/A$0.27 per share34.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.55N/AN/AN/A-42.37%-156.85%-31.92%8/6/2025 (Estimated)CLPTClearPoint Neuro-$18.91M-$0.76N/AN/AN/A-64.51%-78.09%-51.33%8/6/2025 (Estimated)NNOXNano-X Imaging-$53.52M-$0.90N/AN/AN/A-472.19%-30.92%-27.73%8/19/2025 (Estimated)NPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)Latest APYX, NPCE, CLPT, and NNOX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025NPCENeuroPace-$0.24N/AN/AN/A$23.08 millionN/A8/6/2025Q2 2025CLPTClearPoint Neuro-$0.20N/AN/AN/A$9.20 millionN/A5/22/2025Q1 2025NNOXNano-X Imaging-$0.23-$0.21+$0.02-$0.21$3.98 million$3.00 million5/13/2025Q1 2025CLPTClearPoint Neuro-$0.15-$0.22-$0.07-$0.22$8.21 million$8.49 million5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/8/2025Q1 2025APYXApyx Medical-$0.13-$0.10+$0.03-$0.10$9.39 million$9.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ACLPTClearPoint NeuroN/AN/AN/AN/AN/ANNOXNano-X ImagingN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical3.215.454.64CLPTClearPoint NeuroN/A3.532.57NNOXNano-X ImagingN/A5.305.16NPCENeuroPace2.466.635.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%CLPTClearPoint Neuro30.08%NNOXNano-X Imaging21.49%NPCENeuroPace78.83%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%CLPTClearPoint Neuro6.11%NNOXNano-X ImagingN/ANPCENeuroPace20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.79 million32.05 millionOptionableCLPTClearPoint Neuro11027.99 million26.28 millionOptionableNNOXNano-X Imaging19057.78 millionN/AOptionableNPCENeuroPace17032.80 million26.08 millionOptionableAPYX, NPCE, CLPT, and NNOX HeadlinesRecent News About These CompaniesNeuroPace’s SWOT analysis: innovative epilepsy treatment stock faces growth hurdles - Investing.comJuly 8, 2025 | investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. ...July 6, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJuly 2, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 27, 2025 | prnewswire.comNeuroPace Announces Strategic CFO Transition - MorningstarJune 26, 2025 | morningstar.comMNeuroPace, Inc.: NeuroPace Announces Strategic CFO TransitionJune 25, 2025 | finanznachrichten.deINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE - MorningstarJune 24, 2025 | morningstar.comMNeuroPace Announces Strategic CFO TransitionJune 24, 2025 | globenewswire.comNPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law FirmJune 24, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 23, 2025 | globenewswire.comPalumbo Wealth Management LLC Has $567,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE)June 23, 2025 | marketbeat.comNPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law FirmJune 22, 2025 | gurufocus.comNPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law FirmJune 22, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. ...June 22, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 22, 2025 | prnewswire.comNeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 22, 2025 | marketbeat.comNeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician SurveyJune 17, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 16, 2025 | accessnewswire.comANeuroPace’s SWOT analysis: med tech stock poised for growth amid challengesJune 14, 2025 | investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 13, 2025 | accessnewswire.comABronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to ConnectJune 13, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPYX, NPCE, CLPT, and NNOX Company DescriptionsApyx Medical NASDAQ:APYX$2.05 +0.08 (+4.06%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.04 0.00 (-0.24%) As of 07/15/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.ClearPoint Neuro NASDAQ:CLPT$11.15 -0.70 (-5.91%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$11.28 +0.13 (+1.12%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Nano-X Imaging NASDAQ:NNOX$4.91 -0.24 (-4.66%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$4.94 +0.03 (+0.61%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.NeuroPace NASDAQ:NPCE$9.35 -0.20 (-2.09%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$9.35 0.00 (-0.05%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
